ProteoGenix And Bruker Daltonics Inc. (BDAL) Announce Strategic Collaboration For Protein Biomarker Discovery And Screening
10/19/2005 5:09:13 PM
ProteoGenix Inc., a company with broad expertise in genomics and proteomics applied to biomarker discovery, has selected Bruker Daltonics Inc. as a strategic partner for the development of high-throughput protein biomarker discovery and mass spectrometry based multi-analyte assay platforms. One of ProteoGenix' recent successes was the discovery of biomarkers for intra-amniotic infection, published in the Journal of the American Medical Association. ProteoGenix intends to develop these biomarkers into a screening test to identify women at risk for premature birth from the infection. Development of such a non-invasive test may allow treatment early enough to prevent premature birth and has the potential to prevent up to an estimated 175,000 premature births that occur annually in the U.S. due to intra-amniotic infection.
comments powered by